Timolol ( DrugBank: Timolol )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 157 | Sturge-Weber syndrome | 1 |
| 227 | Osler disease | 4 |
157. Sturge-Weber syndrome
Clinical trials : 10 / Drugs : 13 - (DrugBank : 4) / Drug target genes : 5 - Drug target pathways : 63
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01533376 (ClinicalTrials.gov) | February 2012 | 11/2/2012 | Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol | Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol | Sturge Weber Syndrome;Port-wine Mark | Drug: Timolol;Drug: Preservative free artificial tear gel. | Wills Eye | University of Medicine and Dentistry of New Jersey | Terminated | 2 Years | 10 Years | All | 3 | Phase 1 | United States |
227. Osler disease
Clinical trials : 56 / Drugs : 72 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04139018 (ClinicalTrials.gov) | October 20, 2019 | 23/10/2019 | Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia | Efficacy of a Timolol Gel in the Care for Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia: A Double-Blinded, Randomized Controlled Trial | Hereditary Hemorrhagic Telangiectasia | Drug: Timolol Gel;Drug: Placebo Gel | Washington University School of Medicine | NULL | Recruiting | 20 Years | N/A | All | 30 | Phase 2 | United States |
| 2 | NCT02484716 (ClinicalTrials.gov) | June 2015 | 17/6/2015 | Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO) | Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - Randomized Trial Versus Placebo | Telangiectasia, Hereditary Hemorrhagic;Osler Rendu Disease | Drug: Timolol nasal spray;Drug: Placebo nasal spray | Hospices Civils de Lyon | NULL | Completed | 18 Years | N/A | All | 58 | Phase 2 | France |
| 3 | EUCTR2015-000385-55-FR (EUCTR) | 12/05/2015 | 29/03/2017 | Essai d’efficacité du timolol en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler. | TEMPO : Efficacité du TIMOLOL en administration nasale pour le traitement des épistaxis dans la maladie de Rendu-Osler.Essai randomisé en double insu contre placebo - TEMPO | Rendu-Osler disease MedDRA version: 19.1;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Timolol Alcon 0.5% collyre Other descriptive name: TIMOLOL MALEATE | Hospices Civils de Lyon | NULL | Not Recruiting | Female: yes Male: yes | 58 | Phase 2 | France | ||
| 4 | NCT01752049 (ClinicalTrials.gov) | May 2013 | 14/12/2012 | Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept | Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept | Hereditary Hemorrhagic Telangiectasia | Drug: Topical timolol maleate;Drug: placebo saline drops | Unity Health Toronto | University of California, San Francisco;The Hospital for Sick Children;University of Toronto;Sunnybrook Health Sciences Centre;Ryerson University;National Institute of Neurological Disorders and Stroke (NINDS) | Completed | 18 Years | N/A | All | 5 | N/A | Canada |